Trial Profile
Phase I Dose-escalation, Safety / Tolerability and Preliminary Efficacy Study of Intratumoral Administration of GEN0101 in Patients with Advanced Melanoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs GEN 0101 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 01 Aug 2022 Results assessing the safety and tolerability of GEN0101 published in the Cancer Immunology Immunotherapy
- 17 Jan 2017 Status changed from recruiting to completed.
- 07 Jan 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan